1. EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167-85
  2. Marcellin P, et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. AASLD 2013, poster 926
  3. Carosi, G., Rizzetto, M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008;40:603–617
  4. Brunetto MR, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49: 1141-1150
  5. Rijckborst V, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-461
  6. Rijckborst V, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA foe HBeAg-negative patients treated with peginterferon alpha-2a. J Hepatol 2012;56:1006-1011
  7. Marcellin P, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013;7:88-97
  8. Brunetto MR, et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol. 2013;59(6):1153-9
  9. Iannazzo S, et al. Individualized Treatment of HBeAg-negative Chronic Hepatitis B Using Pegylated Interferon-?2a as First-Line and Week-12 HBV DNA/ HBsAg Stopping Rule: A Cost-Effectiveness Analysis. Antivir Ther 2013;18 (4), 623-633
  10. GfK EURISKO. Data on file. Roche, 2013
  11. ISTAT, 2011. Disponibile all'indirizzo:
  12. Libro Bianco AISF 2011. Disponibile all'indirizzo:
  13. Stroffolini T, et al. Current practice of chronic hepatitis B treatment in Southern Italy. Eur J Intern Med. 2012;23(5):e124-7
  14. Marcellin P, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442–55
  15. Lai C-L, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
  16. Hadziyannis SJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
  17. Lai C-L et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
  18. Lampertico P et al. 47th EASL Annual Meeting 2012 Barcelona, Spain
  19. Liaw Y-F, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
  20. Marcellin P et al. 44th EASL Annual Meeting 2009, Copenhagen, Denmark
  21. Fattovich G, et al. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52
  22. Papatheodoridis GV, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.J Hepatol 2010;53:348-56
  23. Veenstra DL, et al. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 2008;27:1240-52
  24. Colombo GL, et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011;3:37-46
  25. Vanagas G, et al. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania. Medicina (Kaunas) 2010;46(12):835-42
  26. FARMADATI Italia, 2013. Compendio Farmaceutico Ospedaliero
  27. Ministero della Salute. Nomenclatore Tariffario Specialistico. GU numero 216, Suppl.
© Effetti srl